1. Home
  2. Live Updates
  3. Important dosing

Live Breaking News & Updates on Important Dosing

Stay updated with breaking news from Important dosing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor ....

United States , Puerto Rico , Davidp Carbone , Laurie Fenton Ambrose , Murdo Gordon , Jay Bradner , Justin Claeys , Teneobio Inc , Beigene Ltd , Chemocentryx Inc , Fast Company , James Thoracic Oncology Center , World Most Innovative Companies , Amgen Safety Net Foundation , Kyowa Kirin Co Ltd , World Health Organization , Drug Administration , Ohio State University Medical Center , American Cancer Society , Exchange Commission , Targeting Therapy , Major Solid , Objective Response Rate , Median Duration , Median Overall Survival , Host Webcast Investor Call ,

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the. ....

Puerto Rico , United States , Justin Claeys , Jay Bradner , Davidp Carbone , Laurie Fenton Ambrose , Murdo Gordon , World Most Innovative Companies , World Health Organization , American Cancer Society , Ohio State University Medical Center , Beigene Ltd , Amgen Safety Net Foundation , Exchange Commission , Kyowa Kirin Co Ltd , Teneobio Inc , Drug Administration , Fast Company , James Thoracic Oncology Center , Chemocentryx Inc , Targeting Therapy , Major Solid , Objective Response Rate , Median Duration , Median Overall Survival , Host Webcast Investor Call ,